CVS Faces Historic Stock Decline Amid Bipartisan Criticism

CVS Health Corp. is experiencing one of the worst months in its history, with its stock price headed towards a twelve-year closing low. Recent bipartisan criticisms from both the right and the left have left CVS and other pharmacy-benefit managers (PBMs) under significant scrutiny, raising questions about the future of these companies.

Criticism from Both Sides of the Aisle

Former President Donald Trump recently made headlines by labeling PBMs as “horrible” middlemen, contributing to the inflated costs of prescription drugs in the United States. During a press conference, Trump stated that Americans pay far too much for prescription medications compared to other countries and pledged to “knock out the middleman.”

This criticism isn’t isolated. Last week, bipartisan legislation was introduced by Massachusetts Democrat Elizabeth Warren and Missouri Republican Josh Hawley, urging companies that own health insurers or PBMs to divest their pharmacy businesses. Such a stance highlights the growing dissatisfaction with the healthcare system and the perceived role of PBMs in driving up drug prices.

CVS’s Recent Financial Struggles

CVS Health Corp. is undoubtedly feeling the impact of these critiques. As of Tuesday morning, CVS shares dropped 2.9%, placing the company on track for its lowest stock close since November 2012. The stock price has plummeted approximately 24.4% in December alone, marking what could be the worst monthly performance since October 2001 when it fell by 28%.

CVS’s troubles are compounded by a broader issue impacting the PBM sector. The Federal Trade Commission (FTC) recently filed lawsuits against PBMs owned by CVS, UnitedHealth, and Cigna, accusing them of artificially inflating prices for essential medicines like insulin. CVS operates as a PBM through its CVS Caremark division, which accounted for 34% of its total revenue of $95.4 billion in the latest quarter.

Market Share Challenges and Stock Performance

Analyst Ann Hynes from Mizuho indicated that CVS may have lost significant market share during the recent Medicare Annual Enrollment Period, which closed on December 7. She noted that CVS diversified its Medicare Advantage plans excessively, potentially leading to overextension of its benefits.

This drop in confidence in CVS’s market position comes as competitors face challenges as well. UnitedHealth has seen its stock fall by 21.5% in December, with CEO Andrew Witty acknowledging the need for healthcare reform, while Cigna’s stock is similarly trending towards a yearly low after a 21.5% dive this month.

Analyst Responses and Future Predictions

Despite the turbulence, some analysts remain optimistic about CVS’s long-term prospects. Morgan Stanley analyst Erin Wright advised investors to resist joining the “sell” bandwagon. While acknowledging the political headwinds and uncertainty the company faces, Wright mentioned that previous attempts at PBM reform have stalled and that the ongoing regulatory landscape could still favor CVS.

Wright maintained her overweight rating on CVS stock, setting a price target of $63, which represents an approximately 39% upside from the current trading levels. This suggests that while CVS is currently fraught with challenges, there remains potential for recovery, contingent on its ability to navigate the changing political and regulatory environment effectively.

Conclusion: A Turning Point for CVS Health

The challenges faced by CVS Health Corp. underscore a moment of reckoning for PBMs and the broader pharmaceutical industry. As criticism mounts from varied political stripes and regulatory scrutiny intensifies, CVS must adapt and respond to these pressures. Whether the company can regain investor confidence and stabilize its stock remains to be seen, but analysts indicate that strategic adjustments could pave the way toward recovery.

In summary, CVS stands at a critical crossroads; its next moves will be pivotal in defining its market position in an increasingly turbulent sector. Stakeholders and investors will be closely monitoring CVS’s actions as the healthcare landscape continues to evolve.

DISCLAIMERS – THIS IS A PAID ADVERTISEMENT.

TipsForTraders.com

This is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public and private companies. By reading this email, our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing.

This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.

For a full disclaimer & disclosure please click here.

This communication is a paid advertisement and is not a recommendation to buy or sell securities. IR PUB Network, and its owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled companies or a third party to disseminate this communication. IThis compensation is a major conflict with our ability to be unbiased, more specifically: This communication is for entertainment purposes only. Never invest purely based on our communication.

Gains mentioned in this article, in our newsletter and on our website may be based on end-of-day or intraday data. Therefore, this communication should be viewed as a commercial advertisement only. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, IR PUB Network often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, and approved by the company that is featured herein, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s).

You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. We have not thoroughly investigated the background of any of the companies we profile. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation.

ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our featured profiles on Companies. Gains mentioned in our website / media webpage(s) may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher.

Blog

CVS Health Faces Historic Stock Plunge Amid Bipartisan Pressure and Criticism